GCM
ADVM

Graham Capital Management’s Adverum Biotechnologies ADVM Stock Holding History

Graham Capital Management’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-11,782
Closed -$80.8K – 1072
2024
Q2 		$80.8K Buy
+11,782
New +$110K ﹤0.01% 959

Other funds holding ADVM

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Graham Capital Management's ADVM Position: Q3 2024 in Review

Graham Capital Management sold out of Adverum Biotechnologies (ADVM) in Q3 2024, closing a stake of 11,782 shares — an estimated $80.8K sold.

Graham Capital Management first reported a position in ADVM in Q2 2024 and held it in 1 quarter. The position peaked at $80.8K in Q2 2024. 77 funds tracked by Wall St. Rank hold ADVM as of Q3 2024.

  • Graham Capital Management reported no remaining Adverum Biotechnologies position as of Q3 2024 after selling out during the quarter.
  • Graham Capital Management sold 11,782 Adverum Biotechnologies shares in Q3 2024, an estimated $80.8K.
  • Graham Capital Management first reported a position in Adverum Biotechnologies in Q2 2024 and held it in 1 quarter.
  • Graham Capital Management's Adverum Biotechnologies position peaked at $80.8K in Q2 2024.
  • 77 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q3 2024.

Based on Graham Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.